Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.

Wood, Martyn D; Sands, Zara A; Vandenplas, Catherine; Gillard, Michel

Wood, Martyn D; Sands, Zara A; Vandenplas, Catherine; Gillard, Michel.

Affiliation

Wood MD; UCB BioPharma SPRL, Braine-l'Alleud, Belgium.
Sands ZA; UCB BioPharma SPRL, Braine-l'Alleud, Belgium.
Vandenplas C; UCB BioPharma SPRL, Braine-l'Alleud, Belgium.
Gillard M; UCB BioPharma SPRL, Braine-l'Alleud, Belgium.

Epilepsia ; 59(9): e147-e151, 2018 09.

Article in En | MEDLINE | ID: mdl-30144048

Subject(s)

Anticonvulsants/pharmacology; Levetiracetam/pharmacology; Membrane Glycoproteins/metabolism; Mutation/genetics; Nerve Tissue Proteins/metabolism; Pyrrolidinones/pharmacology; Anilides/pharmacology; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Membrane Glycoproteins/genetics; Nerve Tissue Proteins/genetics; Protein Binding/drug effects; Protein Binding/genetics; Radioligand Assay; Transfection; Tritium/pharmacokinetics

Key words

antiepileptic drug; epilepsy; modulator; synaptic vesicle protein

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrrolidinones / Membrane Glycoproteins / Levetiracetam / Anticonvulsants / Mutation / Nerve Tissue Proteins Limits: Humans Language: En Journal: Epilepsia Year: 2018 Document type: Article Affiliation country: Belgium Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google